Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma

Event to feature renowned leaders in the field of immunotherapy and neuro-oncology

TORONTO and HOUSTON, Nov. 18, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will host a lunchtime seminar led by key opinion leaders ("KOL"'s) to highlight the current treatment options for recurrent glioblastoma ("rGBM") and the clinical benefits seen with MDNA55, an IL4 receptor targeted therapy in this setting. In addition to the Principal Investigators of the recently completed Phase 2b clinical trial, Dr. John Sampson and Dr. Santosh Kesari, the co-inventor of MDNA55 Dr. Raj Puri, will also participate in the symposium. The event will take place during the Society for Neuro-Oncology ("SNO") annual meeting being held at the JW Marriott Desert Ridge Resort at 5350 E. Marriott Drive in Phoenix, AZ.

The symposium is scheduled for Friday, November 22 from 12:15 to 1:15 PM MT in the Grand Sonoran Room G and will feature presentations as follows:

• Raj Puri, MD, PhD – Director, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, FDA.
  
  
• John H. Sampson, MD, PhD, MHSc, MBA – Robert H. and Gloria Wilkins Distinguished Professor and Chair of Neurosurgery, Department of Neurosurgery, Duke University School of Medicine
  
  
• Santosh Kesari, MD, PhD - Director, Neuro-oncology, Pacific Neuroscience Institute; Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute

The panel will discuss the current unmet medical need for treating individuals with rGBM, the most common and uniformly fatal form of brain cancer, and the potential for an IL4 receptor targeted therapy to combat this disease. The presentation will also highlight key safety and efficacy data from the MDNA55 Phase 2b clinical trial and the positive outcomes seen in patients enrolled in this study.

For information on this event, please send an email request to [email protected].

Medicenna intends to follow this event with a KOL call for investors, analysts and business development professionals. Further information on this event and the KOL call will be released as soon as available.

About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Supported by a US$14.1M non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna's lead IL4-EC, MDNA55, has completed enrolling patients in a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centres in the US. MDNA55 has been studied in five clinical trials involving 132 patients, including 112 adults with rGBM. MDNA55 has demonstrated compelling efficacy and has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA respectively. For more information, please visit www.medicenna.com.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements related to the Phase 2b clinical trial of MDNA55 for the treatment of rGBM and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated June 24, 2019 and in other filings made by the Company with the applicable securities regulators from time to time.

The reader is cautioned that assumptions used in the preparation of any forward-looking information (including, without limitation, the ability of the Company to fully replicate these interim data results) may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.

SOURCE Medicenna Therapeutics Corp.

Related Links

https://www.medicenna.com